Precigen

January 02, 2019

Pharma news over the Christmas period

If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.

Ziopharm stakes its reputation on personalised cell therapy

JP Morgan 2019 – Ziopharm celebrates its divorce with more promises

Pharma news over the Christmas period

Is Spark really worth less than Crispr Therapeutics?

Ziopharm stalls its CAR yet again

Cytokine therapy focus – riding on Nektar’s coattails

Ash 2017 winners and losers – Déjà vu

Ash 2017 preview – Blueprint and Stemline celebrate

Interview – German Merck unveils its secret weapon

Courtesy of Intrexon, a cautionary tale for trusting investors

Winners and losers – An ASH bloodbath

Latest Reports

Biopharma and Medtech Half-Year Review 2021

Evaluate Vantage Biopharma and Venture Capital: A Deep Dive

Editor's Picks

Esmo 2021 – Mirati bids to be belle of the ball

World Lung 2021 preview – China challenges and tremelimumab rises

Roche U-turns and Adaptimmune wins

Tecentriq pullout dominates the latest PD-(L)1 moves

Another gene therapy safety scare hits